ALKERMES reported $-63974000 in Net Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US USD 3.95B 3.03B
Acadia Pharmaceuticals ACAD:US USD -27183000 6.83M
Amgen AMGN:US USD 2.14B 826M
Biogen BIIB:US USD 1.13B 76.7M
Biomarin Pharmaceutical BMRN:US USD -6652000 34.32M
Bluebird Bio BLUE:US USD -76520000 23.62M
Bristol Myers Squibb BMY:US USD 1.61B 185M
Eli Lilly And LLY:US USD 1.45B 499.2M
Gilead Sciences GILD:US USD 1.79B 645M
Intra Cellular Therapies ITCI:US USD -53508000 33.1M
JAZZ PHA JAZZ:US USD -19648000 54.31M
Johnson & Johnson JNJ:US USD 4.46B 356M
Marinus Pharmaceuticals MRNS:US USD 73.29M 112.72M
Merk MRK:US USD 3.25B 696M
Minerva Neurosciences NERV:US USD -6901000 1.82M
Nektar Therapeutics NKTR:US USD -59049000 100.02M
Neurocrine Biosciences NBIX:US USD 68.5M 85.4M
Otsuka Holdings 4578:JP JPY 41.28B 5.22B
Pfizer PFE:US USD 8.61B 1.3B
Regeneron Pharmaceuticals REGN:US USD 1.32B 463.6M
Revance Therapeutics RVNC:US USD -84693000 23.26M
Teva Pharmaceutical Industries TEVA:US USD 55M 288M
Vertex Pharmaceuticals VRTX:US USD 930.5M 120M